摘要
Since the first Palmaz-Schatz bare-metal stent （BMS） was implanted in human body in 1985, coronary stenting successfully resolved problem of the high restenosis rate in balloon dilatation era and soon became the primary means of clinical treatment of coronary artery disease. In order to meet the requirement of further reduction of the restenosis rate, drug-eluting stent （DES） was developed more than a decade later. With the excellent clinical efficacy, DESs established a milestone in the field of percutaneous coronary intervention （PCI）.
Since the first Palmaz-Schatz bare-metal stent （BMS） was implanted in human body in 1985, coronary stenting successfully resolved problem of the high restenosis rate in balloon dilatation era and soon became the primary means of clinical treatment of coronary artery disease. In order to meet the requirement of further reduction of the restenosis rate, drug-eluting stent （DES） was developed more than a decade later. With the excellent clinical efficacy, DESs established a milestone in the field of percutaneous coronary intervention （PCI）.
